Bristol-Myers Squibb Co on Tuesday said it plans this year to begin a late-stage trial testing whether a combination of two of its high-profile immunotherapies can effectively treat lung cancer, easing concerns about the company’s intentions. Company executives spooked investors in January by saying they were not yet planning a late-stage trial that would combine its experimental medicine, nivolumab, and an approved melanoma treatment called Yervoy as a treatment for lung cancer. The company’s cautious timetable suggested to some investors a possible lack of “synergy” between the two drugs when targeting lung cancer.
Help employers find you! Check out all the jobs and post your resume.
